Literature DB >> 8393166

Analysis of the p53 gene in European hepatocellular carcinomas and hepatoblastomas.

B Debuire1, P Paterlini, P Pontisso, G Basso, E May.   

Abstract

Human hepatocellular carcinomas (HCC) and hepatoblastomas (HB) from patients in France and Italy, respectively, which are both areas with a low incidence of HCC and a low dietary exposure to aflatoxin B1 (AFB1), were analysed for alterations of the p53 tumour suppressor gene. An abnormality in the p53 gene was detected in only one of the seven HCCs examined. Sequencing of the cDNA of this HCC revealed a G to T transversion at the first nucleotide of codon 245 that was not found in normal tissue, excluding the possibility of germinal transmission of this alteration. All tumours had the wild-type sequence at codon 249, which has been reported to be a mutational hot spot in the p53 gene in HCCs from high incidence areas, such as China and Southern Africa. Seven samples of HB, the most common hepatic tumour of children, were also tested for loss of heterozygosity (LOH) and mutations in the p53 gene. In contrast to what is observed in HCC of adulthood, for which environmental conditions are important etiological risk factors, HB probably stems uniquely from genetic disorders. PCR-direct sequencing of exons 4 to 8 and PCR-single strand conformation polymorphism (PCRSSCP) of exons 2, 3 and 9 revealed no mutations in the coding sequences examined. LOH was observed in one of the five informative cases when codon 72 and intron 6 were subjected to polymorphism analysis.

Entities:  

Mesh:

Year:  1993        PMID: 8393166

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  Molecular genetics of hepatocellular neoplasia.

Authors:  Shilpa Jain; Shashideep Singhal; Peng Lee; Ruliang Xu
Journal:  Am J Transl Res       Date:  2010-01-23       Impact factor: 4.060

2.  Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications.

Authors:  P C Wu; J W Fang; V K Lau; C L Lai; C K Lo; J Y Lau
Journal:  Am J Pathol       Date:  1996-10       Impact factor: 4.307

3.  Is p53 gene mutation an indicatior of the biological behaviors of recurrence of hepatocellular carcinoma?

Authors:  I-Shyan Sheen; Kuo-Shyang Jeng; Ju-Yann Wu
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

Review 4.  Molecular epidemiology in environmental health: the potential of tumor suppressor gene p53 as a biomarker.

Authors:  J C Semenza; L H Weasel
Journal:  Environ Health Perspect       Date:  1997-02       Impact factor: 9.031

5.  Codon 249 mutation of the p53 gene is a rare event in hepatocellular carcinomas from ethnic Chinese in Singapore.

Authors:  C Y Shi; T W Phang; Y Lin; A Wee; B Li; H P Lee; C N Ong
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

6.  Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma.

Authors:  R Saffroy; J C Lelong; D Azoulay; M Salvucci; M Reynes; H Bismuth; B Debuire; A Lemoine
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

7.  TP53 Mutation in Correlation to Immunohistochemical Expression of P53 Protein in Patients with Hepatocellular Carcinoma.

Authors:  Dafina Nikolova; Viktorija Chalovska-Ivanova; Magdalena Genadieva-Dimitrova; Aleksandar Eftimov; Rubens Jovanovik; Vesna Janevska
Journal:  Open Access Maced J Med Sci       Date:  2018-06-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.